Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis

Kymera Therapeutics, Inc.

KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.
Mean EASI reduction of 63% and mean peak pruritus NRS reduction of 40% across all patients; rapid onset by Day 8.
Type 2 biomarker reductions: TARC down 74% in patients with baseline ≥1,600 pg/mL; Eotaxin-3 reductions numerically exceeded dupilumab at 52 weeks.
First known demonstration of IL-31 reduction and FeNO reduction in AD patients via IL-4/13 pathway blockade.
Well-tolerated with no SAEs, no treatment-related AEs, no conjunctivitis; Phase 2b BROADEN2 ongoing (data mid-2027) and BREADTH asthma trial starts 1Q26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.